Relative to insurance coverage for glucose monitoring.
HB 648 would expand New Hampshire insurance mandates for diabetes care by requiring coverage of glucose monitoring devices and related supplies. The bill amends the state’s insurance statutes governing individual policies, group policies, health service corporations, and health maintenance organizations to require coverage of traditional blood glucose monitors and continuous glucose monitoring systems (CGMS), along with sensors, transmitters, receivers, lancets, and test strips, for people with Type 2 diabetes or gestational diabetes. It also requires coverage for diabetes self-management training and educational services, and preserves existing insulin coverage provisions, including the $30 cap on a 30-day supply and no deductible for covered insulin prescriptions.
The bill further limits utilization controls on glucose monitoring coverage. Insurers could not require prior authorization, an endocrinology referral, insulin use, or a certain frequency of blood testing as a condition of coverage. Coverage would still require periodic follow-up care with a licensed practitioner: every six months during the first 18 months of use, then annually thereafter. The bill would take effect 60 days after passage and would apply across multiple categories of private health coverage regulated under New Hampshire law.
Its impact on state law would be to broaden and standardize mandated diabetes-related benefits across individual and group health insurance, health service corporations, and HMOs. By adding CGMS and associated supplies to required covered benefits, the bill would likely increase claims costs for insurers and could put upward pressure on premiums. The fiscal note also flags possible state fiscal effects, including indeterminable increases in revenue and expenditures and the possibility of state cost defrayal obligations under federal exchange rules if the mandate is treated as an additional essential health benefit.
The general sentiment reflected in the available materials is supportive of expanding access to diabetes monitoring technology, with the bill presented as a consumer and health coverage measure rather than a controversial restructuring of insurance law. The fiscal note and agency analysis acknowledge that the mandate would likely raise costs, but they do not express opposition; instead, they focus on estimating the financial impact and the need for further actuarial review.
The main point of contention is cost and implementation. Insurers and state fiscal analysts are likely to focus on the bill’s potential to increase premiums, claims volume, and administrative obligations, especially because it removes prior authorization and other utilization barriers. Another issue is the scope of the mandate: the bill specifically requires coverage for Type 2 diabetes and gestational diabetes, while also tying continued coverage to follow-up care requirements. No committee transcript or vote record was provided, so there is no documented floor debate or recorded opposition in the supplied materials.
HB 648 would amend RSA 415:6-e, RSA 415:18-f, RSA 420-A:17-a, and RSA 420-B:8-k to require private health insurers, health service corporations, and HMOs to cover glucose monitoring devices and supplies for certain people with diabetes. It would also reinforce existing diabetes coverage rules, including insulin cost-sharing limits, and prohibit deductibles, prior authorization, and endocrinology referral requirements for glucose monitoring coverage. The bill could increase insurance premiums and may create state fiscal exposure if federal exchange defrayal rules apply.
Based on the bill text and fiscal materials, the overall sentiment appears favorable toward expanding diabetes care access, with the measure framed as a coverage expansion for medically necessary monitoring technology. The fiscal note is neutral in tone but cautions that costs are likely to rise and may be indeterminable at this stage. No committee testimony or vote record was provided, so there is no evidence of organized opposition or recorded partisan division in the supplied materials.
The primary contention is financial: insurers and fiscal analysts may object that requiring CGMS coverage, eliminating prior authorization, and limiting cost-sharing will increase claims costs and premiums. A second issue is regulatory scope, including whether the mandate should apply broadly across all covered plans and whether the state could be responsible for defraying costs in the exchange marketplace. The bill’s follow-up care requirement may also be viewed as a compromise between access and utilization control, but no direct testimony is available to show which stakeholders supported or opposed that approach.